Stock Price, News, Quote and Profile of HARROW INC(NASDAQ:HROW) stock

HARROW INC

NASDAQ:HROW (12/20/2024, 8:17:07 PM)

After market: 34.22 0 (0%)

34.22

-0.21 (-0.61%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS SectorHealth Care

GICS IndustryPharmaceuticals

GICS SubIndustryPharmaceuticals

Chartmill FA Rating

Valuation

Growth

Profitability

Health

Dividend

Chartmill High Growth Momentum

EPS Q2Q%7.69%

Sales Q2Q%43.75%

CRS97.04

6 Month62.95%

Overview

Earnings (Last)11-13 2024-11-13/amc

Earnings (Next)N/A N/A

Ins Owners14.01%

Inst Owners54.62%

Market Cap1.22B

Shares35.61M

PEN/A

Fwd PE59.38

Dividend YieldN/A

Analysts84

Short Float %9.32%

Short Ratio5.31

IPO02-08 2013-02-08

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

Harrow, Inc. engages in the development, production, and sale of innovative medications. The company is headquartered in Nashville, Tennessee and currently employs 315 full-time employees. The company went IPO on 2013-02-08. The firm is engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the United States market. The company provides a comprehensive portfolio of prescription and non-prescription pharmaceutical products. The company owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. The company owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. The company owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.